Table 3.
Patient Management Parameters Pre-LAR and Post-LAR
| Interventions | Pre-LAR | Post-LAR | p |
|---|---|---|---|
| Recurrent bleeding management | |||
| Reduced aspirin dose (<325 mg), n (%) | 18 (56.2) | 25 (78.1) | 0.04 |
| Aspirin, n (%) | |||
| None | 8 (25.0) | 18 (56.2) | 0.04 |
| 81 mg | 9 (28.1) | 7 (21.9) | |
| 162 mg | 1 (3.1) | 0 (0) | |
| 325 mg | 14 (43.8) | 7 (21.9) | |
| Reduced INR goal (INR range 2–3), n (%) | 19 (59.4) | 26 (81.3) | 0.02 |
| Dose of LAR (mg), median, [interquartiles] | 30.0 [20.0–40.0] | ||
| Dose frequency of LAR (days), median, [interquartiles] | 28 [21–28] | ||
| Angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist use, n (%) | 19 (59.4) | 15 (46.9) | 0.22 |
| Digoxin use, n (%) | 4 (12.5) | 5 (15.6) | 1.00 |
| CF-LVAD support parameters and durations | |||
| Reduced CF-LVAD rotations per minute, n (%) | 3 (9.4) | ||
| Patient follow-up (days), mean ± SE | 393.5 ± 73.6 | 470.3 ± 57.8 | 0.4 |
| Outcome measures | |||
| Patients with recurrent GIB, n (%) | 32 (100) | 13 (41) | <0.01 |
| Number of GIB median, [interquartiles] | 2.0 [1–3] | 0 [0–1] | <0.01 |
| Frequency of GIB per year, median, [interquartiles] | 2.95 [1.2–5.7] | 0 [0–1.4] | <0.001 |
CF-LVAD, continuous-flow left ventricular assist device; GIB, gastrointestinal bleed; INR, international normalized ratio; LAR, long-acting release.